ISPOR UAE Chapter and AbbVie announce intent to collaborate on healthcare advancement at Abu Dhabi Global Health Week
The LOI signifies a mutual commitment to work together in key areas including Health Technology Assessment (HTA) and policy shaping, as well as research and evidence generation. This collaboration aims to leverage the ISPOR UAE Chapter's extensive network and knowledge in HEOR and AbbVie's scientific expertise to contribute to a more robust and evidence-based healthcare system in the UAE.
Prof. Nadia Al Mazrouei, ISPOR UAE Chapter President, emphasized that 'The ISPOR UAE Chapter is dedicated to fostering excellence in health economics and outcomes research to inform healthcare decisions in the UAE. This Letter of Intent with AbbVie, formalized during the prestigious Abu Dhabi Global Health Week, marks an important step in bridging our network of researchers, policymakers, and healthcare professionals with industry expertise. We are enthusiastic about the potential of this collaboration to generate impactful research and contribute to the development of evidence-based policies that benefit patients across the UAE.'
Elhussein Abdellatif, General Manager Gulf Levant AbbVie, stated, 'We are proud to reaffirm our commitment to elevating the standards of care and enhancing patients' lives. We understand the vital importance of Health Technology Assessment (HTA) and health policy in supporting access to essential therapies. Our collaboration with the ISPOR UAE Chapter provides us with an opportunity to share our expertise and collectively advance toward a more sustainable and patient-focused healthcare ecosystem in the UAE.'
About ISPOR UAE Chapter:
The ISPOR UAE Chapter is the local chapter of ISPOR – the International Society for Pharmacoeconomics and Outcomes Research. It serves as a platform for researchers, policymakers, healthcare professionals, and industry stakeholders in the UAE to advance the science and application of HEOR to improve healthcare decisions.
About AbbVie:
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
01-07-2025
- Zawya
Dubai hosts the 6th edition of the Middle East, Africa and Russia Hematology Summit 'MASH'
Saudi Arabia - The Hematology Medical Conference, sponsored by AbbVie, the global research and development company in the field of biopharmaceuticals, kicked off for the sixth consecutive year at the Intercontinental Festival City, Dubai, UAE. This summit represents a major regional collaboration for medical affairs in the field of hematology, with a robust history of collaboration in five previous successful versions. The summit featured a group of elite national and international experts and more than 25 speakers from across the Middle East, Africa, and Russia, as well as international speakers, including a hematologist from Canada and an AI expert from healthcare practitioners from the United States. This year's Hematology Summit, in its sixth version, focused more on clinical experience, devoting a full day of its program to workshops for hematologists and clinical pharmacists to share their experiences in managing challenging cases. Additionally, specialized workshops on AI role in healthcare and precision medicine, particularly in hematological diseases, were led by an international expert in artificial intelligence. Dr. Ayman Al-Hijazi, Consultant Hematologist, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia, commended the holding of the 6th Hematology Summit and the attendance of that elite group of consultants and hematology experts. The conference showcased the latest diagnostic methods and various advanced treatments in hematology oncology, including AML, CLL, lymphoma, and others. Dr. Ayman also praised the valuable lectures included in the conference, which showcased advancements in the treatment of recurrent or refractory multiple myeloma, as well as revolutionary advances in cancer research and the transformative use of artificial intelligence in diagnosis and personalized treatment strategies. Dr. Abdulwahab Al-Babtain, Consultant Hematologist and Cellular Therapist at King Faisal Specialist Hospital and Research Center in Riyadh, welcomed everyone who participated in the success of this summit. He added that the summit addressed new developments in the treatment of benign and malignant blood diseases and tumors. The conference also featured extensive scientific and medical content, including scientific papers presented and workshops, including workshops on lymphoma and leukemia, management of complications resulting from blood cancers, treatment sequencing for chronic lymphocytic leukemia, and the importance of detecting genetic mutations in acute myeloid leukemia. Dr. Abdulwahab explained that there has been significant development in medications for treating blood diseases, which will significantly contribute to controlling the disease and alleviating patients' suffering. This is based on the latest clinical studies and how to choose the appropriate treatment for each individual case, in accordance with the latest scientific recommendations in this field. Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, emphasized that such scientific summits align with AbbVie's mission and its focus on medical education, training, scientific research, and providing distinguished medical care, in line with the Kingdom's Vision 2030. This was evident in this version of the conference, which showcased the role of AI in accurate disease diagnosis, discussed new treatments for unmet clinical needs, and highlighted the importance of early detection and optimal management of the disease, with the goal of improving patients' lives.
Zawya
15-06-2025
- Zawya
The 5th International Neuroscience Summit for the Middle East, Africa and Russia is being held in Dubai
Saudi Arabia - The International Neurology Conference for the Middle East, Africa and Russia kicked off in Dubai, in cooperation with AbbVie, the global biopharmaceutical research and development company, with the participation of an elite group of international and national speakers and in the presence of several consultants, specialist physicians, researchers, professors and neurology experts from Gulf countries, Saudi Arabia, Egypt and Russia, in addition to several international, regional and local medical associations. The conference included several scientific lectures that discuss the latest research and treatment methods for many neurological diseases such as Parkinson's disease, migraine and post-stroke spasticity. Dr. Abdulrazzaq Al-Bilali, Headache Specialist and Head of the Saudi Headache Chapter, Saudi Neurology Society, commended the continuous efforts of the organizers of this major conference and its success for the fifth consecutive year. Dr. Abdulrazzaq emphasized that scientific research is the cornerstone of progress in the field of neurology. He explained that headache is a health problem that significantly impacts people's lives and daily activities, and that significant developments have occurred in diagnostic methods and disease management. He emphasized that the future of patient care lies in innovation and evidence-based knowledge. For his part, Dr. Suhail Al Rukun, consultant neurology, President of Emirates neurology Society in the United Arab Emirates, praised the large turnout at the conference, which included valuable medical discussions, workshops, and a review of the latest recommendations from clinical trials and research in this sector, in addition to presenting the best methods used in the management of patients with neurological diseases. Dr. Suhail added that this prominent scientific event is a good opportunity to exchange experiences and keep up with the latest developments in the neurology field. Organizing this summit for the fifth consecutive year embodies the ongoing commitment to enhancing medical knowledge and achieving the best treatment outcomes for patients. These initiatives help improve the quality of healthcare and open new horizons for improving patients' lives. Mohammad Aboubakr, Vice President and General Manager of AbbVie's Middle East, Africa & Russia region, commended the launch of the fifth Neurology Summit, which highlighted the latest emerging scientific and medical developments. He emphasized that organizing the summit reflects AbbVie's commitment to enhancing scientific training and research programs and providing a high level of medical care to serve society members by providing what helps improve their quality of life. The company seeks to help make a real difference in patients' lives, as well as its commitment to raising awareness and health education for patients, and on the other hand, its focus on the fields of education, training and scientific research. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Zawya
15-05-2025
- Zawya
Saudi Arabia hosts landmark Ophthalmology Meeting to advance (DME) and (RVO) Treatment
Under the title 'Holistic pro-Inflammatory Target for Sight (HITS)' the Ophthalmology Pivotal Meeting kicked off in Saudi Arabia on April 25, 2025, under the auspices of AbbVie, the global biopharmaceutical research and development company. This is a significant move to elevate the standard of care for various eye conditions like Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). More than 100 national and international ophthalmologists participated in the meeting, which included scientific lectures and in-depth workshops to leverage applied medical specialties in ophthalmology and optics, exchange knowledge and expertise, and help change perspectives on the best ways to improve patient outcomes. It also discussed treatment and management methods of these prevalent diseases. In his lecture, Dr. Mattias Iglicki, Consultant Ophthalmologist, Vitreoretinal Surgeon and Researcher from University of Buenos Aires, Argentina, praised the convening of this meeting, which is a good opportunity to discuss the latest advancements and clinical trials in the presence of this elite group of international retinal specialists, along with local experts. He explained that diabetic macular edema, which is often the result of high blood sugar levels in diabetics, accompanied with leaky blood vessels leading to swelling in the retina. On the other hand, retinal vein occlusion occurs when the retinal veins are blocked, causing fluid buildup and impaired vision. Both conditions are serious and require proactive management to prevent the disease from worsening. Dr. Iglicki emphasized that organizing such medical summits and conferences serves as a platform for sharing and disseminating the cutting-edge research and developments in treating eye diseases, especially DME and RVO, which are diseases whose rates are increasing with the increasing incidence of diabetes. This enables the attending ophthalmologists to implement these updates in their practices, which in turn advances treatment methods in the Kingdom of Saudi Arabia in accordance with the latest international recommendations and technologies, thus improving the lives of patients and alleviating their daily suffering. For his part, Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, pointed out that Saudi Arabia's hosting of such medical meetings and seminars reflects the Kingdom's interest in promoting medical education and exchanging scientific expertise between international and local physicians to highlight the most important scientific and medical developments and provide distinguished medical care. By organizing this congress, AbbVie underscores its commitment to enhancing patient outcomes through educational initiatives and collaboration among eye care professionals. Sharing knowledge and expertise at such events is crucial to our ongoing efforts to refine treatment strategies, improve patients' quality of life, and help make a real difference in their lives. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.
